Amanta Healthcare Q2 FY27 Share Price & Earnings Call Analysis

₹234.47+2.67% today
Market cap
₹910 Cr
P/E
49.65
ROE
10.34%
PEG
0.44
Price to sales
3.00
Debt to equity
0.89
52W high / low
₹234 / ₹95.0
Sales growth (5Y)
10.93%
EBITDA margin
20.45%
Net profit margin
5.69%
Promoter holding
63.80%
Sales (last year)
₹303 Cr

Guidance scorecard · Q2 FY27 call

What Amanta Healthcar's management guided

RevenueQ2 FY27 call

20–40%
  • FY '28 top line target: INR 400-420 crore, including SVP line contribution.
  • SVP (Small Volume Parenterals) line expected to start in Q1 FY '28 with gradual utilization ramp-up to 45-50% by first two quarters.
  • New SVP line aimed at inhalation and ophthalmic products; 20-product pipeline with 12 in SVP segment.
  • SteriPort Line 3 operational since September, expected to contribute INR 60 crore in FY '27; full capacity utilization from November 20.
  • Long-term growth strategy targets 20%+ CAGR revenue growth and 25%+ EBITDA margin.
  • Expansion driven by increased capacity, product development, and geographical market deepening including India, Australia, Canada, South Africa, and parts of Europe.

2 more points from Amanta Healthcar's call on revenue

Create a free account to keep reading this call

Full Q2 FY27 analysis

MarginsQ2 FY27 call

Flat

See what Amanta Healthcar said on margins — free account, 30 seconds.

Full Q2 FY27 analysis

CapexQ2 FY27 call

Planned
  • The company has recently commissioned SteriPort Line 3 (Sept 2026) with full capacity utilization expected by Nov 20, 2026.
  • The next major CapEx is for the SVP (Small Volume Parenterals) facility expansion, targeted to be operational in Q1 FY 2028.
  • Post SVP expansion, future CapEx will focus mainly on product development (20 products in pipeline, especially inhalation and ophthalmic portfolios) and plant automation to reduce manpower and improve efficiency.
  • Annual CapEx after SVP is expected to be between INR7-20 crore, primarily for product pipeline, dossiers, regulatory filings, and automation.
  • No immediate plan for further CapEx in SteriPort beyond existing capacity (12 crore bottles/year).

2 more points from Amanta Healthcar's call on capex

Create a free account to keep reading this call

Full Q2 FY27 analysis

FundraisingQ2 FY27 call

Planned

See what Amanta Healthcar said on fundraising — free account, 30 seconds.

Full Q2 FY27 analysis

Order bookQ2 FY27 call

  • The company expects steady order inflow, supported by new capacity coming online.
  • SteriPort Line 3, commissioned in September 2026, is ramping up and expected to contribute about INR60 crore in top line for FY '27.
  • The SVP line, expected to be commissioned by Q1 FY '28, targets inhalation and ophthalmic products, with a product pipeline of 20, of which 12 are for SVP.
  • Utilization of SVP line expected to be around 40%-50% in initial quarters post-commissioning, with conservative revenue guidance of INR16 crore for FY '27-28, potentially up to INR35-60 crore depending on product mix.

2 more points from Amanta Healthcar's call on the order book

Create a free account to keep reading this call

Full Q2 FY27 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

This quarter's potential multibaggers
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. 3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Amanta Healthcare latest results (Sep 2026)

Revenue

₹83 Cr

+17.27% YoY

Net profit

₹5 Cr

+302% YoY

Operating margin

20.68%

EPS

₹1.25

What management said on the call →

Amanta Healthcare shareholding (Sep 2026)

Promoters

63.80%

+0.01 pp QoQ

FIIs

0.07%

−0.36 pp QoQ

DIIs

12.20%

−0.72 pp QoQ

Public

23.93%

+1.09 pp QoQ

Amanta Healthcar announcements

All announcements →

Financials of Amanta Healthcar

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Amanta Healthcar

Shareholding breakup across reporting periods.

Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +63.56%63.56%63.72%63.79%63.80%
FIIs +1.00%1.10%0.85%0.43%0.07%
DIIs +11.34%11.24%12.88%12.92%12.20%
Public +24.10%24.09%22.55%22.84%23.93%
No. of Shareholders18,66916,18115,22212,61212,319

Financials of Amanta Healthcar

Quarterly Results

Quarter-by-quarter operating performance

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +68.1066.7367.8172.0665.3170.8974.4976.9968.8083.13
YoY Sales growth-4.10%+6.23%+9.85%+6.84%+5.34%+17.27%
Expenses +54.7052.8552.7553.1050.4156.2459.1362.0354.2665.94
Operating Profit13.4013.8815.0618.9614.9014.6515.3614.9614.5417.19
OPM %19.68%20.80%22.21%26.31%22.81%20.67%20.62%19.43%21.13%20.68%
Other Income +0.150.210.870.160.96-2.560.681.660.640.76
Interest9.456.325.906.286.295.155.064.256.005.84
Depreciation4.604.604.514.694.644.664.674.754.695.28
Profit before tax-0.503.175.528.154.932.286.317.624.496.83
Tax %-28.00%28.71%22.64%26.87%28.80%46.93%26.47%27.43%26.28%28.84%
Net Profit +-0.362.264.285.963.511.214.635.533.314.86
EPS in Rs-0.130.781.482.071.220.311.191.420.851.25

Financials of Amanta Healthcar

Profit & Loss

Annual income statement trend

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +184171225259280275288303
Sales growth-7%+32%+15%+8%-2%+5%+10%
Expenses +147133173206223215228241
Operating Profit3738525358606062
OPM %20%22%23%20%21%22%21%20%
Other Income +217641114
Interest3840493534282121
Depreciation1617171820181919
Profit before tax-15-186235152125
Tax %25%23%11%179%32%29%30%
Net Profit +-19-2255-24101518
EPS in Rs-7.03-8.1420.54-0.791.353.643.834.71
Dividend Payout %0%0%0%0%0%0%0%

Financials of Amanta Healthcar

Balance Sheet

Capital structure and asset base

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital2727272727293939
Reserves2-2036363968181189
Borrowings +231235226216211204244204
Other Liabilities +1271501049675819397
Total Liabilities388392392374352382558529
Fixed Assets +244242240232228217207321
CWIP000907820
Investments02304876
Other Assets +144149149133120150262201
Total Assets388392392374352382558529

Financials of Amanta Healthcar

Cash Flows

Operating, investing and financing cash movement

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +38316243584748
Cash from Investing Activity +-9-13-6-7-10-24-94
Cash from Financing Activity +-37-18-50-42-46-23126
Net Cash Flow-8-06-61-181
Free Cash Flow271952364626-32
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit102%66%119%93%111%84%93%

Financials of Amanta Healthcar

Ratios

Working capital efficiency and return ratios

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1041107375636755
Inventory Days225422338247309464530
Days Payable99186185130129194230
Cash Conversion Cycle229345226193243336354
Working Capital Days51-5284216266
ROCE %9%14%13%14%15%12%

Guidance history

How Amanta Healthcar's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q2 FY27 call →20–40%FlatPlannedPlanned—
Q1 FY27 call →10–20%FlatPlanned——
Q4 FY26 call →10–20%FlatPlanned——
Q3 FY26 call →20–40%FlatPlannedPlanned—

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

94out of 100

Momentum score · price trend

94 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,938 stocks
Last 12 months+97.6%92%
Last 6 months+81.2%94%
Last 3 months+50.0%98%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,938 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Amanta Healthcar: 0.4 × 92 + 0.4 × 94 + 0.2 × 98 = 94.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 13 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Amanta Healthcare: frequently asked questions

What is Amanta Healthcare share price today?

Amanta Healthcare last traded at ₹234.47, with a market capitalisation of ₹910 Cr and a P/E ratio of 49.6.

What were Amanta Healthcare's latest quarterly results?

For the quarter ended Sep 2026, Amanta Healthcare reported revenue of ₹83 Cr (+17.27% year on year) and net profit of ₹5 Cr, with an operating margin of 20.68%.

Is Amanta Healthcare's profit growing?

Net profit was ₹5 Cr in Sep 2026 against ₹1 Cr in Sep 2025, a change of +302%.

What is Amanta Healthcare's EPS?

Amanta Healthcare's earnings per share for the quarter ended Sep 2026 was ₹1.25.

What is the promoter holding in Amanta Healthcare?

Promoters held 63.80% of Amanta Healthcare in Sep 2026 (+0.01 pp versus Jun 2026).

How much do FIIs and DIIs hold in Amanta Healthcare?

In Sep 2026, foreign institutional investors held 0.07% and domestic institutions (including mutual funds) held 12.20% of Amanta Healthcare.

What is Amanta Healthcare's ROE and ROCE?

Amanta Healthcare's return on equity is 10.3% and its return on capital employed is 11.6%.

Does Amanta Healthcare pay a dividend?

Amanta Healthcare's dividend yield is 0% at the current price; see the Amanta Healthcare dividends page for past payouts.

What did Amanta Healthcare's management say on the latest earnings call?

Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Amanta Healthcare's management.

How does Arthneeti AI analyse Amanta Healthcare?

Arthneeti reads Amanta Healthcare's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.